Home Markets Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled...

Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractor…

2
investorsdiurnal business news magazine

This post was originally published on this site

<p xmlns="https://www.w3.org/1999/xhtml">SUZHOU and <span class="xn-location">SHANGHAI, China, <span class="xn-chron">Dec. 5, 2020 /PRNewswire/ – Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today…